(LMAT) LeMaitre Vascular - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 2.163m USD | Total Return: 14.8% in 12m
Avg Turnover: 26.7M
EPS Trend: 99.2%
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
Confidence
LeMaitre Vascular, Inc. specializes in the development and distribution of medical devices and implants tailored for vascular surgery. Its product portfolio includes human tissue allografts, biologic patches derived from bovine materials, and specialized catheters for clot removal and blood flow occlusion. The company also provides surgical tools such as valvulotomes and titanium clip closure systems, serving markets across the Americas, Europe, and the Asia Pacific.
The vascular surgery sector is characterized by high barriers to entry due to stringent regulatory approval processes for biologic implants and human tissue processing. LeMaitre utilizes a hybrid business model, leveraging a direct sales force in major markets while employing distributors to reach smaller international territories. This niche focus allows the company to compete by providing specialized instruments that larger, diversified med-tech firms may overlook.
For a deeper look into the companys historical performance and valuation metrics, consider reviewing the data on ValueRay.
- Higher average selling prices for biologic patches and allografts drive margin expansion
- Expanding direct sales force in international markets accelerates organic revenue growth
- Strategic acquisitions of niche vascular devices provide inorganic earnings diversification
- Regulatory approval timelines for new cryopreserved tissue products impact market entry
- Shift toward minimally invasive procedures creates competitive pressure on traditional surgical tools
| Net Income: 62.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 1.63 > 1.0 |
| NWC/Revenue: 173.4% < 20% (prev 169.4%; Δ 3.98% < -1%) |
| CFO/TA 0.14 > 3% & CFO 87.3m > Net Income 62.4m |
| Net Debt (-156.5m) to EBITDA (83.5m): -1.87 < 3 |
| Current Ratio: 14.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.0m) vs 12m ago 0.58% < -2% |
| Gross Margin: 72.39% > 18% (prev 0.69%; Δ 7.17k% > 0.5%) |
| Asset Turnover: 43.23% > 50% (prev 40.69%; Δ 2.54% > 0%) |
| Interest Coverage Ratio: 14.07 > 6 (EBITDA TTM 83.5m / Interest Expense TTM 5.19m) |
| A: 0.71 (Total Current Assets 477.8m - Total Current Liabilities 33.4m) / Total Assets 629.5m |
| B: 0.31 (Retained Earnings 194.7m / Total Assets 629.5m) |
| C: 0.12 (EBIT TTM 73.1m / Avg Total Assets 592.8m) |
| D: 0.86 (Book Value of Equity 191.1m / Total Liabilities 222.9m) |
| Altman-Z'' = 7.37 = AAA |
| DSRI: 0.90 (Receivables 35.8m/35.1m, Revenue 256.3m/226.3m) |
| GMI: 0.95 (GM 72.39% / 68.80%) |
| AQI: 0.86 (AQ_t 0.16 / AQ_t-1 0.19) |
| SGI: 1.13 (Revenue 256.3m / 226.3m) |
| TATA: -0.04 (NI 62.4m - CFO 87.3m) / TA 629.5m) |
| Beneish M = -3.18 (Cap -4..+1) = AA |
As of June 02, 2026, the stock is trading at USD 91.42 with a total of 245,221 shares traded.
Over the past week, the price has changed by -6.48%,
over one month by -18.20%,
over three months by -14.47% and
over the past year by +14.75%.
LeMaitre Vascular has received a consensus analysts rating of 3.73. Therefore, it is recommended to hold LMAT.
- StrongBuy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 118.8 | 29.9% |
P/E Trailing = 34.7978
P/E Forward = 32.8947
P/S = 8.5346
P/B = 5.5472
P/EG = 2.7419
Revenue TTM = 256.3m USD
EBIT TTM = 73.1m USD
EBITDA TTM = 83.5m USD
Long Term Debt = 168.9m USD (from longTermDebt, last quarter)
Short Term Debt = 3.45m USD (from shortTermDebt, last quarter)
Debt = 210.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 20.9m
Net Debt = -156.5m USD (calculated: Debt 210.8m - CCE 367.2m)
Enterprise Value = 2.01b USD (2.16b + Debt 210.8m - CCE 367.2m)
Interest Coverage Ratio = 14.07 (Ebit TTM 73.1m / Interest Expense TTM 5.19m)
EV/FCF = 27.64x (Enterprise Value 2.01b / FCF TTM 72.6m)
FCF Yield = 3.62% (FCF TTM 72.6m / Enterprise Value 2.01b)
FCF Margin = 28.32% (FCF TTM 72.6m / Revenue TTM 256.3m)
Net Margin = 24.35% (Net Income TTM 62.4m / Revenue TTM 256.3m)
Gross Margin = 72.39% ((Revenue TTM 256.3m - Cost of Revenue TTM 70.8m) / Revenue TTM)
Gross Margin QoQ = 72.72% (prev 71.66%)
Tobins Q-Ratio = 3.19 (Enterprise Value 2.01b / Total Assets 629.5m)
Interest Expense / Debt = 2.46% (Interest Expense 5.19m / Debt 210.8m)
Taxrate = 20.30% (3.99m / 19.7m)
NOPAT = 58.2m (EBIT 73.1m * (1 - 20.30%))
Current Ratio = 12.73 (Total Current Assets 477.8m / Total Current Liabilities 37.5m)
Debt / Equity = 0.52 (Debt 210.8m / totalStockholderEquity, last quarter 406.6m)
Debt / EBITDA = -1.87 (Net Debt -156.5m / EBITDA 83.5m)
Debt / FCF = -2.16 (Net Debt -156.5m / FCF TTM 72.6m)
Total Stockholder Equity = 385.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.53% (Net Income 62.4m / Total Assets 629.5m)
RoE = 16.19% (Net Income TTM 62.4m / Total Stockholder Equity 385.4m)
RoCE = 13.18% (EBIT 73.1m / Capital Employed (Equity 385.4m + L.T.Debt 168.9m))
RoIC = 9.71% (NOPAT 58.2m / Invested Capital 599.6m)
WACC = 7.43% (E(2.16b)/V(2.37b) * Re(7.96%) + D(210.8m)/V(2.37b) * Rd(2.46%) * (1-Tc(0.20)))
Discount Rate = 7.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.41 | Cagr: 1.12%
[DCF] Terminal Value 77.97% ; FCFF base≈65.6m ; Y1≈75.2m ; Y5≈110.6m
[DCF] Fair Price = 79.69 (EV 1.66b - Net Debt -156.5m = Equity 1.82b / Shares 22.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.19 | EPS CAGR: 35.83% | SUE: 0.31 | # QB: 0
Revenue Correlation: 99.85 | Revenue CAGR: 14.02% | SUE: -0.11 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.81 | Chg30d=+6.66% | Revisions=+64% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.73 | Chg30d=+1.66% | Revisions=+25% | Analysts=9
EPS current Year (2026-12-31): EPS=3.00 | Chg30d=+3.36% | Revisions=+50% | GrowthEPS=+19.1% | GrowthRev=+12.2%
EPS next Year (2027-12-31): EPS=3.26 | Chg30d=+2.24% | Revisions=+50% | GrowthEPS=+8.5% | GrowthRev=+9.2%
[Analyst] Revisions Ratio: +64%